Navigation Links
Constipation Drug Linked to Heart Attack Pulled Out

Novartis AG, the Swiss pharmaceutical giant, has agreed to stop selling Zelnorm, a constipation drug, following complaints that it is linked// to higher chances of heart attack and stroke.

Officials of the Food and Drug Administration (FDA) of the US had advised the firm to pull the drug out of the market. (It is this Novartis that has challenged the rejection of its patent application for a cancer drug by Indian authorities. The suit has been filed in Madras High Court in southern India and the verdict is eagerly awaited as this is the first test case for India’s patent laws under the WTO regime.)

Earlier the FDA had approved Zelnorm, also called tegaserod maleate, for short-term treatment of women with irritable bowel syndrome with constipation.

It could also be used by those suffering from constipation but below 65 years of age.

It had been available in the market since 2002 and the FDA approval was granted in September 2004. Interestingly right at the time it was granting approval, the FDA had warned of diarrhea risks associated with the drug.

It said then that it had received several complaints of ischemic colitis, a condition resulting from reduced blood flow to the intestines, which in some cases can cause serious intestinal damage, and rarely death.

It had gone on to add, 'FDA is not thinking of taking Zelnorm off the market at this time. We are adding new information about potential risks of treatment with Zelnorm to the labeling so that doctors and patients can make informed individual treatment decisions.'

But now it says that it has concluded that the overall risk versus benefit profile for the drug is unfavorable for continued marketing.

Its request to Novartis was based on 'newly available information of an increased risk of serious cardiovascular adverse events, including myocardial infarction (heart attack), unstable angina (chest pain), and stroke, associated with us e of the drug.'

Doctors who prescribe Zelnorm should work with their patients and switch over to more appropriate treatment, the FDA has said.
GP
'"/>




Related medicine news :

1. Link between Constipation and Parkinsons Disease
2. Constipation can be a cause
3. Tegaserod offers relief for Chronic Constipation
4. Biofeedback Treats One Type Of Chronic Constipation
5. Low Cholesterol Linked to Severe Depression and Violent Behavior in Men
6. Cough Syrup Ingredient Linked to Stroke
7. Irregular Periods Linked to Diabetes
8. Hormones Linked To Migraines
9. Triglycerides Linked To Stroke Risk
10. Smoking Linked To Low Infant Birth Weight
11. Nausea Linked To Anxiety And Depression
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... Illinois (PRWEB) , ... March 29, 2017 , ... ... Stencils Device Library for documenting and diagramming network and data center assets and ... , NetZoom subscribers can request new equipment shapes for free and download shapes ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
(Date:3/29/2017)... Richmond, VA (PRWEB) , ... March 29, 2017 , ... ... of its seventh North American office location in Richmond, Virginia, located at the Riverfront ... April 11, attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... is the first technology to directly address the resolution to globally reduce the ... is a patented compound of FDA and TTB approved ingredients that when infused ...
(Date:3/28/2017)... ... 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid ... Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog and ... NOT the only solution to deal with thyroid disease. , Dr. Wentz completed ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care ... a new PhRMA report on patient out-of-pocket spending: ... Medicare and Medicaid Services (CMS), the average amount spent ... 13% of drug spending in 2016, down from 23% ... a pricing problem, not a coverage problem. Health plans ...
(Date:3/29/2017)... March 29, 2017  Designers of primary cell wearable ... size by 50% and extend battery life with the ... integrated circuit (PMIC) from Maxim Integrated Products, Inc. (NASDAQ: ... low input voltage of just 0.7V for new high-energy ... Oxide, as well as the more common Alkaline battery ...
(Date:3/29/2017)... 2017   Royal Philips (NYSE: PHG, ... and PathAI, a company that develops artificial intelligence ... to develop solutions that improve the precision and ... diseases. The partnership aims to build deep learning ... artificial intelligence to be applied to massive pathology ...
Breaking Medicine Technology: